Sarilumab for recalcitrant cystoid macular edema in non-paraneoplastic autoimmune retinopathy
Conclusion:
Management of CME in non-paraneoplastic autoimmune retinopathy is challenging, and long-term immunosuppression is often employed with varying degrees of success. The improvement in refractory CME and perivascular leakage in this case supports the potential role of an IL-6 inhibitor to treat CME associated with non-paraneoplastic autoimmune retinopathy suggesting the role.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research
More News: Angiography | Brain | Corticosteroid Therapy | Humira | Neurology | Opthalmology | Paraneoplastic Syndrome | Vitamin A